within Pharmacolibrary.Drugs.ATC.C;

model C09AA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09AA10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Trandolapril is an angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension and heart failure. It is an oral prodrug that is converted to its active metabolite, trandolaprilat, in the liver. Trandolapril is currently approved and used for the management of high blood pressure and to improve survival after myocardial infarction.</p><h4>Pharmacokinetics</h4><p>Single-dose, healthy adult volunteers, mixed sex, orally administered; PK parameters refer to trandolapril (parent drug), not active metabolite trandolaprilat.</p><h4>References</h4><ol><li><p>Lenfant, B, et al., &amp; Strauch, G (1994). Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. <i>Journal of cardiovascular pharmacology</i> 23 Suppl 4 S38–S43. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7527100/&quot;>https://pubmed.ncbi.nlm.nih.gov/7527100</a></p></li><li><p>Li, X, et al., &amp; Ding, Y (2016). Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 41(4) 373–384. DOI:<a href=&quot;https://doi.org/10.1007/s13318-015-0277-2&quot;>10.1007/s13318-015-0277-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25864194/&quot;>https://pubmed.ncbi.nlm.nih.gov/25864194</a></p></li><li><p>Wang, X, et al., &amp; Zhu, HJ (2021). Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. <i>Clinical and translational science</i> 14(4) 1380–1389. DOI:<a href=&quot;https://doi.org/10.1111/cts.12989&quot;>10.1111/cts.12989</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33660934/&quot;>https://pubmed.ncbi.nlm.nih.gov/33660934</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09AA10;
